Related Experiment Video
Updated: Jun 6, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue]
Zhen Wang1, Yilong Wu, Guochun Zhang
1Guandong Provincial People's Hospital Cancer Center,Guangdong Provincial Cardiovascular Institute,Guangdong Provincial Lung Cancer Research Institute,Guangdong Provincial People's Hospital Medical Research Center,Guangzhou,Guangdong 510800,P.R.China.
Background:
The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) is playing an important role in the treatment of non-small cell lung cancer.The acquired resistance of EGFR-TKI has become a hot spot.This study aims to investigate VEGF-D expression level in lung adenocarcinoma with or without acquired resistance to gefitinib and in normal lung,so as to explore the role of VEGF-D in resistance of gefitinib.
Methods:
Lung adenocarcinoma,normal lung tissues adjacent to the carcinoma and adenocarcinoma with acquired resistance to gefitinib including some metastastic lymph nodes were obtained during operation.SYBR Green real-time PCR with beta actin gene as the endogenous control was performed to examine VEGF-D gene expression semi-quantitatively.After positive expression of VEGF-D was determined,the expression ratio and level in each group was analyzed qualitatively and quantitatively.
Results:
Exact significance was computed to compare VEGF-D expression ratios in groups of lung adenocarcinoma with acquired resistance to gefitinib(1/6,16.7%),lung adenocarcinoma(7/14,50.0%) and normal lung(16/16,100.0%) and the difference was significant(P=0.000 091 7).VEGF-D relative expression level in the seven lung adenocarcinoma cases was significantly lower than its corresponding normal lung tissue by analysis of nonparametric test(P < 0.01).
Conclusions:
VEGF-D has a high-level expression in normal lung tissues,while has a decreased expression in lung adenocarcinoma with or without acquired resistance to gefitinib,suggesting that VEGF-D functions in lung adenocarcinoma with or without acquired resistance to gefitinib in a way,which is different from in normal lung.
Insights
Vascular endothelial growth factor D (VEGF-D) is highly expressed in normal lung tissue but decreased in lung adenocarcinoma, even with acquired resistance to gefitinib. This suggests VEGF-D plays a distinct role in lung adenocarcinoma compared to normal lung tissue.
Area of Science:
- Molecular oncology
- Biomarkers in cancer research
Context:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial for non-small cell lung cancer treatment.
- Acquired resistance to EGFR-TKIs presents a significant clinical challenge.
Purpose:
- To investigate the expression levels of VEGF-D in lung adenocarcinoma with and without acquired resistance to gefitinib.
- To explore the potential role of VEGF-D in gefitinib resistance.
Summary:
- VEGF-D gene expression was assessed using SYBR Green real-time PCR in lung adenocarcinoma, gefitinib-resistant lung adenocarcinoma, and normal lung tissues.
- VEGF-D expression was significantly higher in normal lung tissues (100%) compared to lung adenocarcinoma (50%) and gefitinib-resistant lung adenocarcinoma (16.7%).
- A significant decrease in VEGF-D relative expression was observed in lung adenocarcinoma compared to adjacent normal lung tissue.
Impact:
- VEGF-D expression is downregulated in lung adenocarcinoma, irrespective of gefitinib resistance.
- The distinct expression pattern suggests VEGF-D may have a role in lung adenocarcinoma pathogenesis or progression, differing from its function in normal lung tissue.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019